Special Issue

Pharmacogenomics and Precision Medicine in Psychiatry: From Basic Research to Clinical Practice

Message from the Guest Editor

Over the past decade, the prevalence of mental illnesses has been steadily increasing worldwide, but the precise diagnosis, treatment selection, and prevention of mental illnesses lag woefully behind. The etiopathology, diagnostic precision, and targeted pharmacotherapies will undoubtedly benefit mentally ill individuals while also enhancing our ability to detect predisposition and vulnerabilities toward mental illness, thereby enabling effective preventive measures. Recent impressive advancements in specific laboratory measures, sophisticated imaging techniques, psychoneuroimmunology, genomics, epigenetics, polygenic risk factors, pharmacogenomics, translational, and precision psychiatry hold great promise. Innovative therapeutic agents based on new scientific discoveries will lessen the personal and societal burden of mental illness. Original research papers, brief scientific reports, as well as review papers, concerning any psychiatric and neuropsychiatric disorder, will be considered for publication in this Special Issue, titled "Pharmacogenomics and Precision Medicine in Psychiatry: From Basic Research to Clinical Practice".

Guest Editor

Prof. Dr. Angelos Halaris

Department of Psychiatry, Loyola University Stritch School of Medicine, Maywood, IL 60153, USA

Deadline for manuscript submissions

closed (10 May 2023)

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).